Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — Investor Presentation (November 2026)
15 slides from Neurizon Therapeutics's investor presentation, Nov 5, 2026
Slide 1: Investor webinar reminder and presentation
Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Investor webinar reminder and presentation Highlights: Shareholders and interested investors are invited to join Neurizon’s investor webinar featuring CEO Dr For personal use only Chris Bremer and CFO Mr Dan O’Connell Investor web
Slide 2: Neurizon Investor Hub
Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Neurizon Investor Hub We encourage you to utilise our Investor Hub for any enquiries regarding this For personal use only announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share
Slide 3: A strengthened funding position ahead of HEALEY trial topline
rsonal use only A strengthened funding position ahead of HEALEY trial topline Shareholder webinar – 5 November 2026 Dr Chris Bremer, Chief Executive Officer Dan O'Connell, Chief Financial Officer ABN 35 094 006 023
Slide 4: Disclaimer
Disclaimer This presentation has been prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”). This Future Matters disclaimer applies to the presentation and all information contained in it. It does not purport to contain all the information that a prospective investor may require in co
Slide 5: Our Vision
rsonal use only Our Vision To lead the development of treatments towards a promising new horizon for people living with neurodegenerative diseases.
Slide 6: Neurizon: A late clinical-stage biotech developing therapies for neurodegenerative diseases
Neurizon: A late clinical-stage biotech developing therapies for neurodegenerative diseases Lead ALS/MND program in Phase 2/3, with topline results expected in late Q2 CY2027 rsonal use only LEAD ASSET: NUZ-001 Investigational oral small molecule being developed initially in ALS/MND and currently ev
Slide 7: Why look now
Why look now A randomised Phase 2/3 readout in late Q2 2027 is the next value inflection rsonal use only 1 2 Late Q2 2027 Clinical advancement Supply chain readiness for scale Expected topline from the 250- participant Phase 2/3 ALS trial. A 250-participant randomised Phase 2/3 enrolled Long-term su
Slide 8: Placement and Share Purchase Plan (SPP) overview
Placement and Share Purchase Plan (SPP) overview $6.3m in new equity targeted, with the convertible notes now fully redeemed rsonal use only PLACEMENT SHARE PURCHASE PLAN OPTIONS CONVERTIBLE NOTES ON ISSUE $4.3m Target $2m 1 for 1 Nil Firm commitments at 6.8c per Eligible shareholders can apply One
Slide 9: Why we acted now
Why we acted now Underpinned by clinical and operational momentum rsonal use only WHERE THE PROGRAM IS THE OPERATING BACKDROP 1 Fully enrolled with topline pending Capital Structure Simplification HEALEY Regimen I: 250 participants in under five months, a record for The convertible note facility cre
Slide 10: SPP rationale and overview
SPP rationale and overview Acting in the best interest of shareholders rsonal use only Outstanding Obsidian notes Equal opportunity for SPP offer metrics: 1 2 redeemed participation All remaining notes redeemed for cash: 1,750,000 The SPP offers the same 6.8c price and the same 20.9% in total have b
Slide 11: Indicative timetable
Indicative timetable Event Dates (Melbourne time) SPP record date 7.00pm, Friday, 30 October 2026 Pre-market Monday, 2 November 2026 rsonal use only Announce results of Placement, announce SPP, trading halt lifted and return to trading on the ASX Settlement of New Shares under the Placement2 Friday,
Slide 12: Near term value catalysts
Near term value catalysts Multiple workstreams underway to drive shareholder value rsonal use only Area Development Indicative timing Preclinical Further Preclinical Insights into Mechanism of Action of NUZ-001 Mid Q4 CY2026 First HEALEY Regimen I participant completes Randomised Treatment phase and
Slide 13: A roadmap to topline readout and beyond
A roadmap to topline readout and beyond Multiple material developments converging over the coming quarters rsonal use only Q4 CY2026 CY2027 Q2 CY2027 Late Q2 CY2027 Post-topline Expanding Pre-Clinical Expanded Access Trial completion and HEALEY topline Regulatory Evidence opens database lock engagem
Slide 14: Investment summary
Investment summary A defining randomised readout in late Q2 CY2027, with groundwork in place rsonal use only 1 A 250-participant randomised Phase 2/3 in ALS, efficiently run Late Q2 2 Record enrolment within the HEALEY platform, in under five months CY2027 3 Early clinical signals that shaped the Ph
Slide 15: Thank You
rsonal use only Thank You Registered Address: Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000 Australia +61 (3) 9692 7222 enquiries@neurizon.com
Neurizon Therapeutics — Investor Presentation (November 2026) on 6ix